The November stock market rally is picking up steam and expanding into more than just the Magnificent Seven stocks. We created an IBD MarketSmith screen that identified stocks that rocked the most in the past month.
Each has gained over 50% for the month. The list found dozens of stocks with the highest price gains that are priced over $12 per share.
CRISPR Soars On Drug News
Making the list is CRISPR Therapeutics. Shares have soared around 85% in November in heavy volume. CRSP holds a 96 Relative Strength Rating.
CRSP jumped after U.K. regulators awarded conditional approval for its gene CRISPR treatment for sickle cell disease on Nov. 16. CRISPR partners with Vertex Pharmaceuticals on the drug.
CRSP tapped the 72 buy point of a cup base on Monday. The stock traded heavily in November and retook its 200-day moving average as it rallied to new highs. Its relative strength line hit a 52-week high on its weekly chart, according to MarketSmith.
Golden Heaven Group has gained around 67% for the month. The stock got rattled after a Nov. 13 Hindenburg Research short report sent shares tumbling.
"Golden Heaven strongly believes that the carelessly assembled report contains numerous errors of facts, misleading speculations and malicious interpretations of events surrounding the Company's operations," Barron's reported Nov. 16.
Shares rebounded following Golden's statement. The Chinese amusement park operator had its initial public offering on April 12 priced at $4 per share. The stock currently trades around $23.
Fiber Optics Stock Sizzles In Current Stock Market
Applied Optoelectronics has climbed 80%.
Shares initially fell after the fiber-optics maker reported a third-quarter loss that was in line with estimates and sales that missed views Nov. 9.
AAOI climbed five out of the last six days and reclaimed its 50-day moving average Nov. 13. It is forming a cup base with a 16.26 buy point.
| Ticker | RS Rating | Composite Rating | 30-Day % Gain | |
|---|---|---|---|---|
| CRISPR Therapeutics | CRSP | 96 | 84 | 85% |
| Golden Heaven Group | GDHG | 99 | 81 | 67% |
| Applied Optoelectronics | AAOI | 99 | 78 | 80% |
| Arcellx | ACLX | 99 | 75 | 53% |
| JAKKS Pacific | JAKK | 96 | 72 | 77% |
Drug Stock Rallies In November Stock Market
Arcellx surged 53% in the past 30 days. Shares broke out of a cup-with-handle base with a 48.38 buy point Nov. 15.
The move came on news that the cancer therapy company deepened its partnership with Gilead Sciences' Kite division on their cancer treatments. The expanded collaboration will provide Arcellx with an upfront cash payment of $85 million and a $200 million equity investment in ACLX stock.
ACLX pulled back 4.7% on Monday, but remains extended from the 5% buy range. Arcellx is not profitable and is expected to continue to show losses through 2024.
JAKKS Pacific stock popped 77% in the last 30 days in heavy volume. The toy manufacturer's shares are above the 20% profit zone from a double-bottom base with a 21.84 buy point. Shares hit a 52-week high on Monday. The stock took off following the company's stellar third-quarter earnings report on Nov. 1.
Follow Kimberley Koenig for more stock market news on X/Twitter @IBD_KKoenig.
